Takeda announced that the FDA has approved a labeling update for Trintellix to include new head-to-head clinical data comparing it to Lexapro for improving treatment-emergent sexual dysfunction.
Flibanserin can be safely added to a stable SSRI or SNRI regimen to treat hypoactive sexual desire disorder.
Men, including male physicians, are less likely than female physicians to seek medical treatment for their own health conditions.
Flibanserin may improve some measures of sexual dysfunction in premenopausal women.
A clinician should also rule out the possibility that the dysfunction stems from a co-occurring medical or psychiatric condition, or substance abuse.
Awareness of adolescents' sexual history is essential in providing mental health treatment.
Researchers found that the brains of those with compulsive sexual behaviors "lit up" in the same way as drug addicts' brains.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Cannabis Use in Adolescence Associated With Poorer Mental Health Outcomes
- Cardioprotective Treatment May Reduce Adverse Effects in Schizophrenia
- Insomnia in Borderline Personality Disorder May Increase Suicide Risk
- FDA Approves Powerful New Opioid Despite Criticisms
- The Challenges of Identifying Biomarkers of Psychiatric Illness
- Heart Rate Variability Predicts Treatment Response in Anxious Depression
- Impulsivity in Bipolar Disorder, Borderline Personality Disorder, ADHD
- Psychotropic Medication May Reduce Symptoms and Improve Functioning in PTSD
- Social Decline a Predictor of Conversion Outcome in High-Risk Individuals
- Buprenorphine/Samidorphan Helpful in Refractory Depression